Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES ANALYSIS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISING INCIDENCE OF DRUG ABUSE
5.1.2 GROWING EMPHASIS ON WORKPLACE SAFETY
5.1.3 GROWTH IN HOME AND PARENTAL DRUG TESTING KITS
5.1.4 RISING USE OF POC TESTING IN HEALTHCARE FACILITIES
5.2 RESTRAINTS
5.2.1 DATA SECURITY AND PRIVACY CONCERNS
5.2.2 LACK OF ACCURACY AND TECHNICAL CHALLENGES
5.3 OPPORTUNITIES
5.3.1 GROWING AWARENESS AND THE CAMPAIGN FOR DRUG TESTING
5.3.2 STRATEGIC INITIATION AND DECISION TAKEN BY THE MARKET PLAYERS
5.3.3 EXPANDING PRODUCT RANGE FOR POINT-OF-CARE DRUG ABUSE TESTING
5.4 CHALLENGES
5.4.1 LIMITED AWARENESS AND ACCEPTANCE
5.4.2 HIGH COSTS ASSOCIATED WITH THE TESTING
6 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE
6.1 OVERVIEW
6.2 AMPHETAMINES
6.3 OPIATES
6.4 CANNABINOIDS
6.5 COCAINE
6.6 BARBITURATES
6.7 BENZODIAZEPINES
6.8 METHADONE
6.9 PHENCYCLIDINE
6.1 TRICYCLIC ANTIDEPRESSANTS
6.11 OTHERS
7 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS
7.1 OVERVIEW
7.2 DEVICES
7.2.1 ANALYZER
7.2.1.1 IMMUNOASSAY ANALYZER
7.2.1.1.1 HIGH VOLUME
7.2.1.1.2 MID VOLUME
7.2.1.1.3 LOW VOLUME
7.2.1.2 BREATHALYZER
7.2.1.2.1 ELECTROCHEMICAL FUEL CELL BREATH ANALYZERS
7.2.1.2.2 INFRARED OPTICAL SENSOR BREATH ANALYZERS
7.2.1.2.3 SEMICONDUCTOR BREATH ANALYZERS
7.2.2 RAPID DEVICES
7.2.3 DRUG TESTING CASSETTE
7.2.4 DRUG TESTING CUPS
7.2.5 DIP CARDS/STRIPS
7.2.6 ORAL FLUID TESTING DEVICES
7.2.7 OTHERS
7.2.8 MODALITY
7.2.9 HANDHELD
7.2.10 MOBILE
7.2.11 MANUAL
7.2.12 AUTOMATED
7.3 CONSUMABLES AND ACCESSORIES
7.3.1 ASSAY KITS AND REAGENTS
7.3.2 PROBES
7.3.3 OTHERS
7.3.3.1 DAST-10
7.3.3.2 Plasma Protein Binding
7.3.3.3 Plasma and Serum Stability
7.3.3.4 Others
7.3.3.4.1 Multi-Panel Drug Test Kits
7.3.3.4.2 Single-Panel Drug Test Kits
8 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION
8.1 OVERVIEW
8.2 OVER THE COUNTER TESTING
8.3 PRESCRIPTION-BASED TESTING
9 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE
9.1 OVERVIEW
9.2 URINE
9.3 SALIVA
9.4 BLOOD
9.5 HAIR
9.6 BREATH
9.7 OTHERS
10 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE
10.1 OVERVIEW
10.2 RANDOM TESTING
10.3 POST-INCIDENT TESTING
10.4 ABSTINENCE TESTING
11 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 MEDICAL SCREENING
11.3 WORKPLACE SCREENING
11.4 LAW ENFORCEMENT AND CRIMINAL JUSTICE
11.5 PAIN MANAGEMENT
11.6 SUBSTANCE ABUSE TREATMENT AND REHABILITATION
11.7 PARENTAL OR HOME DRUG TESTING
11.8 SPORTS AND ATHLETICS TESTING
11.9 DRUG SCREENING IN SCHOOLS AND EDUCATIONAL INSTITUTIONS
11.1 OTHERS
12 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER
12.1 OVERVIEW
12.2 HEALTHCARE FACILITIES
12.2.1 HOSPITALS
12.2.2 EMERGENCY DEPARTMENT
12.2.3 CENTRAL LABS
12.2.4 CLINICS
12.2.5 POISON CONTROL CENTERS
12.2.6 OTHERS
12.3 EMPLOYERS
12.4 GOVERNMENT INSTITUTES
12.5 OTHERS
13 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
13.4 OTHERS
14 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION
14.1 NORTH AMERICA
14.1.1 U.S.
14.1.2 CANADA
14.1.3 MEXICO
15 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
16 SWOT ANALYSIS
17 COMPANY PROFILES
17.1 ABBOTT LABORATORIES
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 SIEMENS HEALTHINEERS AG
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 QUEST DIAGNOSTICS INCORPORATED
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 THERMO FISHER SCIENTIFIC INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 F.HOFFMAN-LA ROCHE LTD.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT UPDATES
17.5.6 RECENT UPDATES
17.6 ACCUBIOTECH CO., LTD.
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENT
17.7 ADVACARE PHARMA
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT UPDATES
17.8 AGILENT TECHNOLOGIES, INC
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT UPDATES
17.9 ASSURE TECH (HANGZHOU) CO., LTD.
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 BD
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 BEIJING HOTGEN BIOTECHN CO., LTD.
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENT
17.12 BIOEASY BIOTECHNOLOGY CO., LTD.,
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.13 BIO-RAD LABORATORIES, INC.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 CLIAWAIVED, INC.
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.15 DRUGSCAN
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 EGENS GROUP (NANTONG YISHI BIOTECHNOLOGY CO., LTD.)
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENT
17.17 HANGZHOU ALLTEST BIOTECH CO.,LTD
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 JOYSBIO (TIANJIN) BIOTECHNOLOGY CO., LTD
17.18.1 COMPANY SNAPSHOT
17.18.2 PRODUCT PORTFOLIO
17.18.3 RECENT UPDATES
17.19 LIFESIGN LLC.
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENT
17.2 MERCK KGAA
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENTS
17.21 MP BIOMEDICALS
17.21.1 COMPANY SNAPSHOT
17.21.2 PRODUCT PORTFOLIO
17.21.3 RECENT DEVELOPMENT
17.22 PREMIER BIOTECH, INC.
17.22.1 COMPANY SNAPSHOT
17.22.2 PRODUCT PORTFOLIO
17.22.3 RECENT DEVELOPMENT
17.23 SYSMEX CORPORATION
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENTS
17.24 WONDFO
17.24.1 COMPANY SNAPSHOT
17.24.2 PRODUCT PORTFOLIO
17.24.3 RECENT DEVELOPMENT
17.25 XIAMEN BOSON BIOTECH CO., LTD.
17.25.1 COMPANY SNAPSHOT
17.25.2 PRODUCT PORTFOLIO
17.25.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 2 NORTH AMERICA AMPHETAMINES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 3 NORTH AMERICA OPIATES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 4 NORTH AMERICA CANNABINOIDS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 5 NORTH AMERICA COCAINE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 6 NORTH AMERICA BARBITURATES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 7 NORTH AMERICA BENZODIAZEPINES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 8 NORTH AMERICA METHADONE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 9 NORTH AMERICA PHENCYCLIDINE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 10 NORTH AMERICA TRICYCLIC ANTIDEPRESSANTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 11 NORTH AMERICA OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 12 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 13 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 14 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 15 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 16 NORTH AMERICA ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 17 NORTH AMERICA IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 18 NORTH AMERICA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 19 NORTH AMERICA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 20 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 21 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 22 NORTH AMERICA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 23 NORTH AMERICA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 24 NORTH AMERICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 25 NORTH AMERICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 26 NORTH AMERICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 27 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 28 NORTH AMERICA OVER THE COUNTER TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 29 NORTH AMERICA PRESCRIPTION-BASED TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 30 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 31 NORTH AMERICA URINE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 32 NORTH AMERICA SALIVA IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 33 NORTH AMERICA BLOOD IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 34 NORTH AMERICA HAIR IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 35 NORTH AMERICA BREATH IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 36 NORTH AMERICA OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 37 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 38 NORTH AMERICA RANDOM TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 39 NORTH AMERICA POST-INCIDENT TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 40 NORTH AMERICA ABSTINENCE TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 41 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 42 NORTH AMERICA MEDICAL SCREENING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 43 NORTH AMERICA WORKPLACE SCREENING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 44 NORTH AMERICA LAW ENFORCEMENT AND CRIMINAL JUSTICE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 45 NORTH AMERICA PAIN MANAGEMENT IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 46 NORTH AMERICA SUBSTANCE ABUSE TREATMENT AND REHABILITATION IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 47 NORTH AMERICA PARENTAL OR HOME DRUG TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 48 NORTH AMERICA SPORTS AND ATHLETICS TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 49 NORTH AMERICA DRUG SCREENING IN SCHOOLS AND EDUCATIONAL INSTITUTIONS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 50 NORTH AMERICA OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 51 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 52 NORTH AMERICA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 53 NORTH AMERICA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 NORTH AMERICA EMPLOYERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 55 NORTH AMERICA GOVERNMENT INSTITUTES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 56 NORTH AMERICA OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 57 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 58 NORTH AMERICA DIRECT TENDER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 59 NORTH AMERICA RETAIL SALES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 60 NORTH AMERICA OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 61 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 62 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 63 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 64 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 65 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 66 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 67 NORTH AMERICA ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 68 NORTH AMERICA IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 69 NORTH AMERICA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 70 NORTH AMERICA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 71 NORTH AMERICA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 72 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 73 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 74 NORTH AMERICA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 75 NORTH AMERICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 76 NORTH AMERICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 77 NORTH AMERICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 78 NORTH AMERICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 79 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 80 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 81 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 82 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 83 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 84 NORTH AMERICA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 85 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 86 U.S. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 87 U.S. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 88 U.S. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 89 U.S. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 90 U.S. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 91 U.S. ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 92 U.S. IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 93 U.S. BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 94 U.S. BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 95 U.S. BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 96 U.S. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 97 U.S. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 98 U.S. CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 99 U.S. ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 100 U.S. ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 101 U.S. ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 102 U.S. ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 103 U.S. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 104 U.S. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 105 U.S. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 106 U.S. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 107 U.S. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 108 U.S. HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 109 U.S. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 110 CANADA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 111 CANADA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 112 CANADA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 113 CANADA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 114 CANADA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 115 CANADA ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 116 CANADA IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 117 CANADA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 118 CANADA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 119 CANADA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 120 CANADA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 121 CANADA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 122 CANADA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 123 CANADA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 124 CANADA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 125 CANADA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 126 CANADA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 127 CANADA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 128 CANADA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 129 CANADA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 130 CANADA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 131 CANADA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 132 CANADA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 133 CANADA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 134 MEXICO POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 135 MEXICO POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 136 MEXICO DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 137 MEXICO DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 138 MEXICO DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 139 MEXICO ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 140 MEXICO IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 141 MEXICO BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 142 MEXICO BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 143 MEXICO BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 144 MEXICO DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 145 MEXICO DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 146 MEXICO CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 147 MEXICO ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 148 MEXICO ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 149 MEXICO ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 150 MEXICO ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 151 MEXICO POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 152 MEXICO POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 153 MEXICO POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 154 MEXICO POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 155 MEXICO POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 156 MEXICO HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 157 MEXICO POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
List of Figure
FIGURE 1 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: END USER COVERAGE GRID
FIGURE 8 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: SEGMENTATION
FIGURE 11 TEN SEGMENTS COMPRISE THE NORTH AMERICA POINT-OF-CARE DRUG ABUSE TESTING MARKET, BY DRUG TYPE
FIGURE 12 EXECUTIVE SUMMARY
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 RISING INCIDENCE OF DRUG ABUSE IS DRIVING THE GROWTH OF THE NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET FROM 2024 TO 2031
FIGURE 15 THE AMPHETAMINES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOB POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET IN 2024 AND 2031
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET
FIGURE 17 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DRUG TYPE, 2023
FIGURE 18 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)
FIGURE 19 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 20 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 21 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRODUCTS 2023
FIGURE 22 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRODUCTS, 2024-2031 (USD THOUSAND)
FIGURE 23 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRODUCTS, CAGR (2024-2031)
FIGURE 24 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRODUCTS, LIFELINE CURVE
FIGURE 25 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRESCRIPTION, 2023
FIGURE 26 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRESCRIPTION, 2024-2031 (USD THOUSAND)
FIGURE 27 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRESCRIPTION, CAGR (2024-2031)
FIGURE 28 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRESCRIPTION, LIFELINE CURVE
FIGURE 29 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY SAMPLE TYPE, 2023
FIGURE 30 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY SAMPLE TYPE, 2024-2031 (USD THOUSAND)
FIGURE 31 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY SAMPLE TYPE, CAGR (2024-2031)
FIGURE 32 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY SAMPLE TYPE, LIFELINE CURVE
FIGURE 33 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY TESTING TYPE, 2023
FIGURE 34 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY TESTING TYPE, 2024-2031 (USD THOUSAND)
FIGURE 35 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY TESTING TYPE, CAGR (2024-2031)
FIGURE 36 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY TESTING TYPE, LIFELINE CURVE
FIGURE 37 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY APPLICATION, 2023
FIGURE 38 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY APPLICATION, 2024-2031 (USD THOUSAND)
FIGURE 39 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY APPLICATION, CAGR (2024-2031)
FIGURE 40 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 41 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY END USER, 2023
FIGURE 42 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 43 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY END USER, CAGR (2024-2031)
FIGURE 44 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 45 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 46 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)
FIGURE 47 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 48 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 49 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: SNAPSHOT (2023)
FIGURE 50 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: COMPANY SHARE 2023 (%)
